Clinical Trial: Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

U.S., May 3 -- ClinicalTrials.gov registry received information related to the study (NCT06956092) titled 'Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma' on April 24.

Brief Summary: The goal of this clinical trial is to learn if Glofitamab works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of Glofitamab treatment. The main questions it aims to answer are:

* Does Glofitamab treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?

* What medical problems do participants have when receiving Glofitamab treatment?

In this investigator-initiated, single-arm clinical trial...